HLA-E-restricted HIV-1-specific CD8+ T cell responses in natural infection.


Journal

The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877

Informations de publication

Date de publication:
16 08 2021
Historique:
received: 22 02 2021
accepted: 01 07 2021
pubmed: 7 7 2021
medline: 9 11 2021
entrez: 6 7 2021
Statut: ppublish

Résumé

CD8+ T cell responses restricted by MHC-E, a nonclassical MHC molecule, have been associated with protection in an SIV/rhesus macaque model. The biological relevance of HLA-E-restricted CD8+ T cell responses in HIV infection, however, remains unknown. In this study, CD8+ T cells responding to HIV-1 Gag peptides presented by HLA-E were analyzed. Using in vitro assays, we observed HLA-E-restricted T cell responses to what we believe to be a newly identified subdominant Gag-KL9 as well as a well-described immunodominant Gag-KF11 epitope in T cell lines derived from chronically HIV-infected patients and also primed from healthy donors. Blocking of the HLA-E/KF11 binding by the B7 signal peptide resulted in decreased CD8+ T cell responses. KF11 presented via HLA-E in HIV-infected cells was recognized by antigen-specific CD8+ T cells. Importantly, bulk CD8+ T cells obtained from HIV-infected individuals recognized infected cells via HLA-E presentation. Ex vivo analyses at the epitope level showed a higher responder frequency of HLA-E-restricted responses to KF11 compared with KL9. Taken together, our findings of HLA-E-restricted HIV-specific immune responses offer intriguing and possibly paradigm-shifting insights into factors that contribute to the immunodominance of CD8+ T cell responses in HIV infection.

Identifiants

pubmed: 34228645
pii: e148979
doi: 10.1172/JCI148979
pmc: PMC8363272
doi:
pii:

Substances chimiques

HLA-B Antigens 0
HLA-B57 antigen 0
Histocompatibility Antigens Class I 0
Immunodominant Epitopes 0
Receptors, Antigen, T-Cell, alpha-beta 0
gag Gene Products, Human Immunodeficiency Virus 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI102663
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI162168
Pays : United States

Références

J Transl Med. 2016 Mar 01;14:62
pubmed: 26928826
Antivir Ther. 2005;10(1):95-107
pubmed: 15751767
PLoS One. 2012;7(9):e46120
pubmed: 23049954
Mol Immunol. 2013 Jan;53(1-2):126-31
pubmed: 22898188
J Immunol. 2006 Jun 1;176(11):6690-701
pubmed: 16709828
Immunity. 2015 Sep 15;43(3):591-604
pubmed: 26362266
Hum Immunol. 2004 May;65(5):437-45
pubmed: 15172443
Nat Commun. 2018 Aug 7;9(1):3137
pubmed: 30087334
J Exp Med. 2008 Mar 17;205(3):725-35
pubmed: 18332182
J Virol. 2019 Sep 12;93(19):
pubmed: 31315990
Clin Vaccine Immunol. 2009 Feb;16(2):147-55
pubmed: 19091991
Eur J Immunol. 2002 Apr;32(4):936-44
pubmed: 11920559
J Virol. 2020 Jan 6;94(2):
pubmed: 31645444
Sci Immunol. 2021 Mar 25;6(57):
pubmed: 33766849
PLoS Pathog. 2019 Aug 9;15(8):e1007970
pubmed: 31398241
Curr Opin Immunol. 2017 Aug;47:52-56
pubmed: 28734175
PLoS One. 2016 Feb 10;11(2):e0147812
pubmed: 26863315
Clin Vaccine Immunol. 2010 Sep;17(9):1305-14
pubmed: 20660136
Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10896-901
pubmed: 12960383
J Leukoc Biol. 2015 Apr;97(4):761-7
pubmed: 25713086
Science. 2013 May 24;340(6135):1237874
pubmed: 23704576
Nature. 2011 May 26;473(7348):523-7
pubmed: 21562493
Nucleic Acids Res. 2013 Jan;41(Database issue):D1234-40
pubmed: 23180793
Nature. 2013 Oct 3;502(7469):100-4
pubmed: 24025770
Curr Pharm Des. 2009;15(28):3336-44
pubmed: 19860683
Sci Immunol. 2021 Mar 25;6(57):
pubmed: 33766848
PLoS Pathog. 2018 Apr 30;14(4):e1007041
pubmed: 29709038
Nat Immunol. 2006 Mar;7(3):256-64
pubmed: 16474394
Eur J Immunol. 2001 Dec;31(12):3687-93
pubmed: 11745389
AIDS. 2002 Feb 15;16(3):321-8
pubmed: 11834942
J Acquir Immune Defic Syndr. 2011 Oct 1;58(2):132-40
pubmed: 21637109
Placenta. 2017 Jan;49:33-36
pubmed: 28012452
PLoS One. 2013;8(3):e59210
pubmed: 23527138
J Immunol. 2005 Feb 15;174(4):2116-23
pubmed: 15699142
J Virol. 2021 Jul 26;95(16):e0016021
pubmed: 34076482
Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5199-204
pubmed: 9560253
Retrovirology. 2013 Dec 12;10:152
pubmed: 24330837
J Immunol. 2018 Jul 1;201(1):113-123
pubmed: 29743316
Immunol Lett. 2018 Oct;202:65-72
pubmed: 30172717
PLoS Pathog. 2016 Feb 01;12(2):e1005421
pubmed: 26828202
Mol Immunol. 2020 Apr;120:101-112
pubmed: 32113130
J Infect Dis. 2009 Nov 1;200(9):1397-401
pubmed: 19780673
Eur J Immunol. 2005 Nov;35(11):3240-7
pubmed: 16224817
Science. 1999 Feb 5;283(5403):857-60
pubmed: 9933172
Science. 2021 Apr 30;372(6541):
pubmed: 33766941
Eur J Immunol. 2018 Feb;48(2):293-305
pubmed: 29124751
PLoS One. 2015 Aug 24;10(8):e0135972
pubmed: 26302084
Eur J Immunol. 2010 Jul;40(7):1950-62
pubmed: 20432235
Front Immunol. 2014 Apr 22;5:180
pubmed: 24795723
J Exp Med. 1999 Mar 15;189(6):991-8
pubmed: 10075982
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Science. 2016 Feb 12;351(6274):714-20
pubmed: 26797147
J Virol. 2013 Mar;87(5):2628-38
pubmed: 23255798
J Immunol. 1989 May 1;142(9):3320-8
pubmed: 2785140
PLoS Pathog. 2015 Mar 24;11(3):e1004671
pubmed: 25803478
J Immunol. 2020 Nov 15;205(10):2861-2872
pubmed: 33020145
Immunology. 2014 Jan;141(1):27-38
pubmed: 23941420
PLoS One. 2012;7(11):e50951
pubmed: 23226431
Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14666-70
pubmed: 9405670
J Biol Chem. 2003 Feb 14;278(7):5082-90
pubmed: 12411439
Immunogenetics. 2016 Jan;68(1):29-41
pubmed: 26552660
J Virol. 2007 Mar;81(5):2440-8
pubmed: 17182686
Blood. 2007 Jul 1;110(1):201-10
pubmed: 17371945
J Immunol. 2018 Jan 1;200(1):49-60
pubmed: 29150562
J Exp Med. 2002 Dec 2;196(11):1403-14
pubmed: 12461076
Nature. 2017 Jul 6;547(7661):89-93
pubmed: 28636592
J Immunol. 1998 May 15;160(10):4951-60
pubmed: 9590243
Immunology. 2007 Sep;122(1):90-7
pubmed: 17472719
J Immunol Res. 2016;2016:2695396
pubmed: 27699181
Eur J Immunol. 2020 Dec;50(12):2075-2091
pubmed: 32716529
Retrovirology. 2018 Jul 3;15(1):46
pubmed: 29970102
J Infect Dis. 2019 Oct 8;220(10):1620-1628
pubmed: 31301135
PLoS One. 2017 Nov 27;12(11):e0188288
pubmed: 29176828
J Immunol. 2020 Apr 15;204(8):2169-2176
pubmed: 32161099

Auteurs

Anju Bansal (A)

Department of Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA.

Mika N Gehre (MN)

Department of Biological Sciences, University of Texas at El Paso, El Paso, Texas, USA.

Kai Qin (K)

Department of Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA.

Sarah Sterrett (S)

Department of Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA.

Ayub Ali (A)

Department of Medicine and AIDS Institute, UCLA, Los Angeles, California, USA.

Ying Dang (Y)

Department of Biomedical Sciences, Texas Tech University Health Sciences Center, Paul L. Foster School of Medicine, El Paso, Texas, USA.

Sojan Abraham (S)

Department of Biomedical Sciences, Texas Tech University Health Sciences Center, Paul L. Foster School of Medicine, El Paso, Texas, USA.

Margaret C Costanzo (MC)

Department of Biological Sciences, University of Texas at El Paso, El Paso, Texas, USA.

Leon A Venegas (LA)

Department of Biological Sciences, University of Texas at El Paso, El Paso, Texas, USA.

Jianming Tang (J)

Department of Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA.

N Manjunath (N)

Department of Biomedical Sciences, Texas Tech University Health Sciences Center, Paul L. Foster School of Medicine, El Paso, Texas, USA.

Mark A Brockman (MA)

Simon Fraser University, Burnaby, British Columbia, Canada.

Otto O Yang (OO)

Department of Medicine and AIDS Institute, UCLA, Los Angeles, California, USA.

June Kan-Mitchell (J)

Department of Biological Sciences, University of Texas at El Paso, El Paso, Texas, USA.

Paul A Goepfert (PA)

Department of Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH